Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Natural Course of Muscular Strength, Physical Performance, and Musculoskeletal Symptoms in Hospitalized Patients With COVID-19

Ayça Utkan Karasu, MD,a Levent Karataş, MD,a Yeşim Yıldız, MD,b Zafer Günendi, MDa

From the aDepartment of Physical Medicine and Rehabilitation, Gazi University Faculty of Medicine, Ankara, Turkey; and bDepartment of Infectious Diseases, Gazi University Faculty of Medicine, Ankara, Turkey.

Abstract
Objective: To investigate the course of muscle strength, musculoskeletal symptoms and physical performance over time in hospitalized COVID-19 patients, and their relation with disease severity at admission.

Design: Prospective cohort study.

Setting: Pandemic clinic of Gazi University Hospital, Ankara, Turkey.

Participants: 76 adult COVID-19 patients (aged >18 years) were enrolled in the study between March 2021 and May 2021 (N=76). The participants were grouped as “mild,” “moderate,” and “severe” according to clinical and radiological findings.

Main Outcome Measures: The fraction of inspired oxygen (FiO₂), oxygen saturation (SpO₂), hand grip strength (HGS), 5-times sit and stand test (5XSTS), modified Borg scale at rest (mBorg-rest), modified Borg scale during activities of daily living (mBorg-ADL), Barthel index, and visual analog scale for myalgia (myalgia-VAS) values were recorded on the first day of hospitalization and in the first, third, and 12th weeks. Outcome measures were compared between disease severity groups. In addition, the changes in these outcome measures over time were also examined.

Results: There were 15 (19.7%) participants in the mild, 20 (26.3%) in the moderate, and 41 (53.9%) in the severe groups. At the baseline evaluation, SpO₂ (P<.001), FiO₂ (P<.001), 5XSTS (P=.002), mBorg-rest (P=.016), and mBorg-ADL (P<.001) were different in 3 groups, but there were no differences for HGS, Barthel index, and myalgia-VAS score. HGS, 5XSTS, myalgia-VAS, and mBorg-ADL scores improved significantly over time in all the groups (P<.001, P≤.001, and P<.001, respectively). At the end of 12 weeks, only 5XSTS was different between the groups. 5XSTS was significantly longer in the severe group (P=.010).

Conclusion: Although significant improvement was observed in the muscle strength, physical performance, and musculoskeletal symptoms of patients with COVID-19 over time, the physical performance of these patients did not reach normal standards. We conclude that post-COVID-19 rehabilitation programs are needed to optimize the physical performance of the patients.

The clinical presentation of COVID-19 ranges from asymptomatic illness to mild flu symptoms, pneumonia accompanied by acute respiratory failure or acute respiratory distress syndrome requiring intensive care unit (ICU) admission, and death.1 According to Centers for Disease Control and Prevention data, approximately 14% of patients required hospitalization.2

Accumulating evidences have shown that the musculoskeletal symptoms can occur during the infection, even before the common respiratory symptoms begin (dry cough, nasal congestion, sore throat, and dyspnea). Fatigue, arthralgia, myalgia, and muscle weakness are common symptoms in COVID-19.3,4 The prevalence of myalgia has been reported between 11% and 50% in large cohort studies, regardless of disease severity.5,6 Even months after recovery, patients still complain of musculoskeletal symptoms such as fatigue and muscle pain.7

Muscle weakness and exercise intolerance in COVID-19 patients are multifactorial. The most commonly accepted factors are systemic inflammation, forced physical inactivity or disuse, hypoxemia, malnutrition, and certain medications.8
COVID-19 infection causes acute and severe inflammation. The inflammatory response may include cytokine storm with extremely high levels of proinflammatory mediators such as interleukin-6 and tumor necrosis factor-alpha. Severe inflammation can cause multiple organ damage, including not only the lungs but also the muscles. Another factor that causes muscle weakness and exercise intolerance in these patients is immobility and prolonged bed rest. Immobilization causes significant changes in muscle mass. It can also lead to metabolic dysfunction and worsening of functional status."10 Insufficient food intake may also cause muscle weakness and exercise intolerance in COVID-19 patients. Intense inflammation and proanorectic effect of hypoxia, together with loss of appetite, loss of taste, and smell may cause decreased consumption of nutrients. In addition, severe inflammation accompanying tissue ischemia increases caloric needs.10

Regardless of the causes, it is important to monitor and evaluate the musculoskeletal symptoms and physical performance during the course of the disease and after discharge in COVID-19 patients. There are few studies that evaluated musculoskeletal symptoms and physical performance in COVID-19 patients who do not need intensive care, during hospitalization or after discharge.5,11 None of these studies investigated how musculoskeletal symptoms and physical performance changes during the disease process and whether discharged patients may achieve their ideal physical performance. It is important to know the effect of disease severity on the performance of patients during hospitalization and after discharge. Thus, appropriate rehabilitation programs can be designed for patients with physical performance deterioration.

The aim of this study is to evaluate the relation between disease severity and muscle strength, musculoskeletal system symptoms and physical performance in hospitalized patients with COVID-19, and to examine the change of these clinical parameters throughout the course of the disease.

Methods

Study design and participants

This prospective cohort study was conducted in the pandemic clinic of Gazi University Hospital, which was designated as a COVID-19 hospital by the Turkey Ministry of Health. A total of 76 consecutive hospitalized polymerase chain reaction positive COVID-19 patients were enrolled in the study between March 2021 and May 2021. Written informed consent was obtained from all participants before enrollment. The study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Gazi University clinical research ethics committee (Decision number: 118, February 17th, 2021). This study was registered in ClinicalTrials.gov (number NCT04784546). Pediatric, pregnant, critically ill patients who were admitted initially to ICUs, patients who had neuromuscular, orthopedic, rheumatic diseases, or cancer, and those who did not agree to participate were excluded.

Procedures

Demographic data, hospital length of stay, comorbidities, medications used for COVID-19 treatment, laboratory findings (C-reactive protein, ferritin, D-dimer, white blood cell count, lymphocyte count) at hospitalization were recorded. Fraction of inspired oxygen (FiO2), oxygen saturation (SpO2), hand grip strength (HGS), 5 times sit and stand test (5XSTS), modified Borg scale at rest (mBorg-rest), modified Borg scale during activities of daily living (mBorg-ADL), Barthel index, and visual analog scale for myalgia (myalgia-VAS) were evaluated on the first day of hospitalization. Measurements were repeated at the first, third, and 12th weeks. All assessments were performed by the same physical medicine and rehabilitation specialist. The tests were carried out in the patient’s room at bed side during hospitalization. Post-discharge evaluations were carried out in the outpatient clinic.

Participants were categorized into mild, moderate, or severe groups according to WHO classification. Mild COVID-19 defines as respiratory symptoms without evidence of pneumonia or hypoxia, while moderate or severe infection is defined as the presence of clinical and radiological evidence of pneumonia. In moderate cases, SpO2 ≥90% on room air while 1 of the following was required to define the severe cases: respiratory rate >30 breaths/min or SpO2 <90% on room air.5,12,13

Outcome measures

Information about outcome measures is presented in table 1.

Data analysis

Statistical analyses were made using the IBM SPSS Statistics 20.0 software package (SPSS Inc, Chicago, IL, USA). The Kolmogorov-Smirnov or Shapiro-Wilk tests were used to test for normal distribution. Numerical variables are expressed as mean ± SD. Categorical variables are given as numbers and percentages. Numerical variables were compared using 1-way analysis of variance or the Kruskal-Wallis test, and categorical variables were compared using Chi-square or Fisher’s exact tests. The variation of independent variables over time was evaluated using Friedman test. Wilcoxon signed rank test was used for post hoc pairwise comparisons. Statistical significance was set at P<.05 (P<.008 for post hoc pairwise comparisons).

Results

Seventy-six participants were included in the study between March 2021 and May 2021 (figure 1). At the baseline evaluation, the distribution of mild, moderate, and severe disease was n=15 (19.7%), n=20 (26.3%), and n=41 (53.9%), respectively. Some clinical and demographic characteristics of the participants are summarized in table 2. During the follow-up, 6 participants of the severe disease group were transferred to ICU after the third week. Three of them deceased. All other participants were discharged
There was a statistically significant difference in the HGS over time in all groups (mild: $\chi^2(3)=23.674, P<.001$; moderate: $\chi^2(3)=16.815, P=.001$; severe: $\chi^2(3)=40.079, P<.001$). There was a significant decrease in the 5XSTS scores over time in each group ($P<.001$). The Barthel index increased gradually over time only in the severe group ($\chi^2(3)=13.071, P=.004$). However, there was no difference for paired comparisons ($P>.008$). Myalgia-VAS scores decreased over time in each group (mild group: $\chi^2(3)=20.631, P<.001$; moderate group: $\chi^2(3)=19.388, P<.001$; severe group: $\chi^2(3)=15.400, P=.002$), but there was no statistically significant difference in paired comparisons ($P>.008$). The change in the mBorg-rest score over time in the moderate and severe groups was found to be statistically significant (moderate group: $\chi^2(3)=32.899, P<.001$; severe group: $\chi^2(3)=53.013, P<.001$). The change was significant in mBorg-ADL scores over time in all 3 disease severity groups (mild group: $\chi^2(3)=16.657, P<.001$; moderate group: $\chi^2(3)=40.451, P<.001$; severe group: $\chi^2(3)=78.149, P<.001$).

The weeks in which the change in outcome measures over time was statistically significant are summarized in Table 4.

Baseline and 12th week HGS and 5XSTS values were compared with age and sex-specific normative data. At baseline, HGS was in normal ranges in all participants in the mild group but it was low in 5.3% of the moderate group and in 14.6% of the severe group. At the 12th week, HGS values were in normal ranges in mild and moderate groups and it was low in 7.9% of participants in the severe group. However, these changes over time in HGS were not significant in moderate and severe groups ($P=.317$ and $P=.180$). In the baseline evaluation, the 5XSTS performances (according to the age and sex-specific normative data) were slower in

---

**Table 1: Outcome measures**

| Measure | Assessing | Procedure |
|---------|-----------|-----------|
| HGS     | Indicator of overall muscle strength. HGS was considered low if it was less than fifth percentile of the age and sex-specific peak mean values. | A recently calibrated Jamar Hand Dynamometer (JA Preston Corporation, New York, USA)w was used in the standard position recommended by the American Society of Hand Therapists. Measurements were repeated 3 times at 1-minute intervals. The arithmetic average of the measurements was recorded in kilograms. |
| 5XSTS   | 5XSTS is a reliable tool that can be used to assess lower limb muscle strength, balance, and functional mobility. 5XSTS test was considered abnormal if it was more than 95th percentile of the age and sex-specific peak mean values. | It is a numerical scale consisting of 12 items (0, 0.5, 1-10). Higher scores correspond with increasing shortness of breath. In our study, the mBorg scale was used to measure perceived dyspnea and fatigue symptoms during rest and daily activities. |
| mBorg   | The mBorg scale measures perceived exertion, and effort spent during physical activities. This scale also evaluates the severity of dyspnea at rest. | High scores indicate better performance in the daily life of the patients. |
| Barthel index | The Barthel ADL index is a 10-item scale that is widely used in functional disability. It measures the performance during activities of daily living. | The participants were asked to specify general muscle pain severity at the time of evaluation by indicating a position along a 10-cm long line. In VAS, 0 indicated no pain at all and 10 represented the strongest pain imaginable. |
| myalgia-VAS | A visual analog scale was used to evaluate myalgia. | |

Abbreviation: VAS, visual analog scale.
53.3% of the participants in the mild group, in 84.2% of the participants in the moderate group, and in 76.7% of the participants in the severe group. At the end of the 12th week, these values were 40.0%, 57.9%, and 54.1%, respectively. Although this change was not significant in the mild group ($P = .157$), it was significant in the moderate and severe groups ($P = .025$ and $P = .007$).

**Discussion**

In our study, there were significant differences in hospital length of stay, body mass index, laboratory findings (C-reactive protein, ferritin, lymphocytes, SpO$_2$, FiO$_2$), 5XSTS, mBorg-rest, and mBorg-ADL at the baseline evaluation according to disease severity. However, there were no differences for other clinical variables such as HGS, Barthel index, and myalgia. Our study showed that there was a significant improvement in all clinical parameters in all groups over time. HGS increased significantly, and 5XSTS, myalgia-VAS, and mBorg-ADL scores decreased.

COVID-19 is primarily a respiratory disease but it also affects the musculoskeletal system. Fatigue, myalgia, and arthralgia are common symptoms in COVID-19 patients. Limited data are available on the relation between these symptoms and the severity of the disease. Myofiber necrosis and atrophy secondary to severe COVID-19 have been demonstrated before. Therefore, it may be reasonable to evaluate the change in muscle strength and physical performance during the disease course. There are previous studies evaluating muscle strength in COVID-19. Kara et al reported that the HGS was lower in the severe COVID-19 patients. However, in our study, we did not observe such a difference in the mild, moderate, and severe patients, both during hospitalization and during the 12-week follow-up. This may be related to the fact that the groups in our study were similar in terms of important risk factors such as age, sex, and comorbidities. Another possible explanation for this may be that critically ill patients, who are at higher risk for myofiber necrosis and atrophy, were not included in our study. Although our study did not include a healthy control group, HGS assessments of nearly all patients were found to be normal according to age and sex-related normative HGS data at the end of the 12-week follow-up.

There are studies investigating physical performance of COVID-19 patients in the ICU during and after infection. Medrinal et al reported that severe muscle weakness persists 1 month after discharge from ICU. Muscle weakness after ICU admission is a common problem. The incidence of ICU-acquired weakness depends on age, sex, primary disease, and treatment. Muscular atrophy develops in up to 70% of older patients in the ICU. Our study group consisted of non-ICU COVID-19 patients.
muscular atrophy may not have occurred in our participants. This may be the reason why the HGS and 5XSTS results improved in all groups over time.

Although there was no difference between the disease severity groups in HGS, there was a difference in 5XSTS. There could be several reasons for this. HGS assesses general muscle strength and measures isometric muscle strength in the upper extremity. However, 5XSTS tests transitional movements, functional mobility, balance, and lower extremity strength. Although there is no significant difference in muscle strength according to disease severity in these patients, there may be a difference in transitional movements, balance, and functional mobility. It was observed that 5XSTS scores improved considerably in all groups over time. However, the difference between the groups was still evident after 3 months of follow-up. Therefore, we think that the mBorg can be evaluated together with clinical findings (such as O₂ saturation) and used to manage the pulmonary rehabilitation in patients with COVID-19.

There are previous studies in which the Barthel index was used to evaluate functional independence of COVID-19 patients. Cuerda et al stated that functional independence decreased significantly in COVID-19 patients treated in the ICU. Hosoda and Hamada reported that functional decline in COVID-19 was not related to disease severity. However, the samples of these 2 studies are very different from each other. First study included only the patients who were treated in the ICU, but there were mild and moderate COVID-19 patients in the second study. In our study, Barthel index scores were similar in different disease severity groups at all time points and there was an improvement over time only in the severe group. We think that there is no difference over time in mild and moderate disease groups because all measurements are normal or very close to normal at all time points. So, it would be more appropriate to use this scale only in the severe COVID-19 patients.

There is not a standard rehabilitation program for COVID-19 patients. The need for rehabilitation may depend on the severity of the disease, length of stay in the hospital, and/or ICU because these conditions will affect the physical performance of the patients. Patient’s cardiopulmonary capacity may be the limiting factor during rehabilitation. Therefore, a complete cardiopulmonary evaluation should be performed. All patients requiring rehabilitation after COVID-19 should have a functional assessment to reveal residual musculoskeletal impairments in order to determine

### Table 2 Clinical and demographic characteristics of the study population according to disease severity

|                      | Mild (n=15) | Moderate (n=20) | Severe (n=41) | P Value |
|----------------------|------------|----------------|--------------|---------|
| Age (y)              | 48.2±16.7  | 53.7±13.1      | 57.0±12.7    | .106    |
| Sex (%)              |            |                |              |         |
| Female (n=30)        | 7 (44%)    | 10 (50%)       | 13 (32%)     | .344    |
| Male (n=46)          | 8 (56%)    | 10 (50%)       | 28 (68%)     |         |
| Hospital length of stay (days) | 5.8±3.8    | 6.45±3.9       | 11.6±6.6     | .001*   |
| BMI (kg/m²)          | 26.1±5.4   | 28.7±3.5       | 29.4±3.9     | .032*   |
| Comorbidities        |            |                |              |         |
| Hypertension         | 5 (33.3%)  | 8 (40%)        | 16 (39%)     | .909    |
| Obesity              | 3 (20%)    | 5 (25%)        | 19 (46.3%)   | .098    |
| Diabetes mellitus    | 1 (6.7%)   | 4 (20%)        | 12 (29.3%)   | .190    |
| Hypothyroidism       | 2 (13.3%)  | 1 (5%)         | 2 (4.9%)     | .500    |
| CVD                  | 1 (6.7%)   | 3 (15%)        | 8 (19.5%)    | .503    |
| COPD                 | 0 (0%)     | 4 (20%)        | 2 (4.9%)     | .054    |
| Laboratory           |            |                |              |         |
| WBC (10³/μL)         | 6.4±2.5    | 6.7±3.2        | 6.5±2.5      | .973    |
| Lymphocytes (10³/μL) | 1.5±0.5    | 1.2±0.5        | 0.9±0.5      | <.001*  |
| D-Dimer (μg/mL)      | 0.6±0.5    | 0.6±0.3        | 0.7±0.5      | .319    |
| Ferritin (μg/L)      | 137.4±249.8| 257.2±295.7   | 549.7±612.5  | .001*   |
| CRP (mg/L)           | 33.0±39.7  | 55.7±38.1      | 82.4±76.5    | .007*   |
| Treatment            |            |                |              |         |
| Antiviral            | 15 (100%)  | 20 (100%)      | 41 (100%)    | NA      |
| Antithrombotics      | 13 (87%)   | 20 (100%)      | 41 (100%)    | .015*   |
| Steroids             |            |                |              |         |
| Oral                 | 1 (6.7%)   | 13 (65%)       | 24 (58.5%)   | <.001*  |
| Pulse                | 0 (0%)     | 1 (5%)         | 15 (36.5%)   |         |
| Biopharmaceutical medication | 0 (0%)     | 0 (0%)         | 4 (9.8%)     | .165    |

NOTE. Values are presented as number (%) or mean ± SD. Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CVD, cardiovascular disease; NA, not applicable; WBC, white blood cell. * P<.05.
In post-COVID-19 rehabilitation, it is recommended to start physical activity immediately and to gradually increase regular daily activity for full functional recovery.26,27 The duration and frequency of daily activities and physical rehabilitation should be adjusted according to the patient’s performance. A multicomponent exercise program including aerobic, resistance, balance, coordination, and mobility training exercises is safe and well tolerated. A multicomponent rehabilitation program is ideal. Rehabilitation clinics were converted into pandemic clinics when necessary. For these reasons, patients’ access to rehabilitation has decreased. Appropriate patient selection is very important in order to use limited rehabilitation opportunities rationally and to ensure that patients in need of post-COVID rehabilitation have access to these treatments. For this reason, it is important to choose practical, low-cost, and effective methods that can be required to prevent worsening of respiratory symptoms. During pandemic, post-COVID-19 rehabilitation can be delivered in the hospital, in the outpatient clinic, or at home, depending on the needs of the patient. During the pandemic, the number of patients undergoing rehabilitation was reduced to prevent infection transmission. Rehabilitation clinics were converted into pandemic clinics when necessary. For these reasons, patients’ access to rehabilitation has decreased. Appropriate patient selection is very important in order to use limited rehabilitation opportunities rationally and to ensure that patients in need of post-COVID rehabilitation have access to these treatments. For this reason, it is important to choose practical, low-cost, and effective methods that can be implemented.

### Table 3: Comparison of muscle strength, functional independence, myalgia severity, fatigue, dyspnea, FiO₂, and SpO₂ according to disease severity

|                        | Mild (n=15)         | Moderate (n=20) | Severe (n=41) | P Value |
|------------------------|---------------------|----------------|--------------|---------|
| **HGS (kg)**           |                     |                |              |         |
| Baseline               | 33.6±11.9           | 31.9±8.4       | 31.6±10.4    | .922    |
| First week             | 34.4±11.1           | 33.5±8.9       | 31.8±11.2    | .705    |
| Third week             | 35.7±11.8           | 34.0±8.9       | 33.7±10.8    | .935    |
| 12th week              | 36.3±11.5           | 34.3±8.8       | 35.2±10.1    | .915    |
| **5XSTS (s)**          |                     |                |              |         |
| Baseline               | 10.7±3.2            | 14.7±4.6       | 15.0±3.6     | .002*   |
| First week             | 11.1±1.7            | 12.9±3.5       | 14.9±4.1     | .002*   |
| Third week             | 10.4±1.3            | 11.9±2.5       | 12.0±2.5     | .068    |
| 12th week              | 9.9±1.1             | 10.9±1.8       | 11.6±1.8     | .010*   |
| mBorg-rest             |                     |                |              |         |
| Baseline               | 0.5±1.4             | 1.4±1.7        | 1.5±1.8      | .016*   |
| First week             | 0.4±1.3             | 0.7±1.0        | 1.5±1.7      | .003*   |
| Third week             | 0.0±0.1             | 0.3±0.8        | 0.3±0.9      | .355    |
| 12th week              | 0.0±0.0             | 0.0±0.1        | 0.0±0.0      | .671    |
| mBorg-ADL              |                     |                |              |         |
| Baseline               | 0.7±1.0             | 2.6±2.3        | 3.0±1.9      | <.001*  |
| First week             | 0.3±0.6             | 1.3±1.5        | 2.7±1.9      | <.001*  |
| Third week             | 0.2±0.4             | 0.7±1.2        | 1.0±1.4      | .019*   |
| 12th week              | 0.0±0.0             | 0.1±0.3        | 0.2±0.3      | .123    |
| **Barthel index**      |                     |                |              |         |
| Baseline               | 100±0.0             | 98.5±6.7       | 96.9±8.1     | .085    |
| First week             | 100±0.0             | 99.0±4.5       | 94.0±17.0    | .122    |
| Third week             | 100±0.0             | 96.5±2.2       | 98.1±10.5    | .675    |
| 12th week              | 100±0.0             | 99.5±2.2       | 100±0.0      | .266    |
| **Myalgia-VAS**        |                     |                |              |         |
| Baseline               | 2.3±3.1             | 1.9±2.6        | 1.1±2.3      | .199    |
| First week             | 0.9±1.9             | 1.3±2.1        | 0.7±1.7      | .255    |
| Third week             | 0.3±0.9             | 0.3±0.8        | 0.4±0.9      | .981    |
| 12th week              | 0.0±0.0             | 0.0±0.0        | 0.0±0.0      | NA      |
| **FiO₂**               |                     |                |              |         |
| Baseline               | 21±0.0              | 21.6±2.7       | 29.1±6.7     | <.001*  |
| First week             | 21±0.0              | 21.0±0.0       | 33.8±18.7    | <.001*  |
| Third week             | 21±0.0              | 21.0±0.0       | 23.4±12.7    | .251    |
| 12th week              | 21±0.0              | 21.0±0.0       | 21.0±0.0     | NA      |
| **SpO₂ (%)**           |                     |                |              |         |
| Baseline               | 95.7±1.5            | 93.7±1.8       | 93.4±1.6     | <.001*  |
| First week             | 95.9±1.5            | 95.0±1.7       | 93.1±2.3     | .007*   |
| Third week             | 97.1±1.3            | 96.8±1.1       | 95.6±1.9     | .007*   |
| 12th week              | 97.6±0.8            | 96.6±0.8       | 96.4±1.0     | .001*   |

**Note:** Values are presented as number (%) or mean ± SD.
Abbreviations: NA, not applicable; VAS, visual analog scale.
* P<.05.
Fig 2  Change of HGS and 5XSTS tests over time.

| Group    | Baseline - third week | Z Value | P Value |
|----------|------------------------|---------|---------|
| HGS      | Baseline - 12th week  | -2.972  | .003    |
|          | First week - third week| -2.842  | .004    |
|          | First week - 12th week | -2.938  | .003    |
|          | Baseline - first week  | -3.099  | .002    |
|          | Baseline - third week  | -3.421  | .001    |
|          | Moderate               | Baseline - 12th week | -3.323  | .001    |
|          | Moderate               | Baseline - 12th week | -3.903  | <.001   |
|          | Severe                 | Baseline - 12th week | -4.954  | <.001   |
|          | Severe                 | Third week - 12th week | -3.474  | <.001   |
|          | Mild                   | First week - 12th week | -3.124  | .002    |
|          | Mild                   | Baseline - first week  | -3.099  | .002    |
|          | Mild                   | Baseline - third week  | -3.421  | .001    |
|          | Mild                   | First week - 12th week | -3.501  | <.001   |
|          | Mild                   | Third week - 12th week | -3.340  | .001    |
|          | Moderate               | Baseline - third week  | -3.676  | <.001   |
|          | Moderate               | Baseline - 12th week  | -4.444  | <.001   |
|          | Severe                 | Baseline - third week  | -4.587  | <.001   |
|          | Severe                 | First week - 12th week | -4.954  | <.001   |
|          | mBorg-rest             | Moderate               | Baseline - third week  | -3.209  | .001    |
|          | mBorg-rest             | Baseline - 12th week  | -3.197  | .001    |
|          | mBorg-ADL              | Moderate               | Baseline - third week  | -3.443  | .001    |
|          | mBorg-ADL              | Baseline - 12th week  | -4.575  | <.001   |
|          | mBorg-ADL              | First week - 12th week | -3.550  | <.001   |
|          | mBorg-ADL              | First week - 12th week | -4.421  | <.001   |
|          | Third week - 12th week | -2.831  | .005    |
|          | Third week - 12th week | -3.444  | .001    |
|          | Third week - 12th week | -4.575  | <.001   |
|          | Third week - 12th week | -3.550  | <.001   |
|          | Third week - 12th week | -4.421  | <.001   |
|          | Third week - 12th week | -2.831  | .005    |
|          | Third week - 12th week | -3.444  | .001    |
|          | Third week - 12th week | -4.575  | <.001   |
|          | Third week - 12th week | -3.550  | <.001   |
|          | Third week - 12th week | -4.421  | <.001   |
|          | Third week - 12th week | -2.831  | .005    |
|          | Third week - 12th week | -3.444  | .001    |
|          | Third week - 12th week | -4.575  | <.001   |
|          | Third week - 12th week | -3.550  | <.001   |
|          | Third week - 12th week | -4.421  | <.001   |

Table 4  Statistically significant changes over time
used to identify patients who need rehabilitation. We think that 5XSTS and mBorg scale together with clinical findings can be used to determine rehabilitation needs and to monitor progression in the rehabilitation process.

Study limitations
One of the limitations of our study is the relatively small number of patients. The main reason for this is that the study was conducted in a single center. Because of the ongoing pandemic, the man-power and working time that could be allocated to the study were limited. The lack of a control group including healthy individuals is also a limitation. A comparison with healthy individuals in the study could be useful in demonstrating the change in physical performance due to COVID-19 infection. However, sometimes there were lockdowns in the country, and healthy individuals were asked not to visit hospitals as much as possible. Another limitation is that critical COVID-19 patients are not included. Our study focuses on physical performance in patients with COVID-19; however, it should be kept in mind that most of the tests we evaluated cannot be used efficiently in critically ill patients, almost all of whom are treated in the ICU.

Conclusions
Borg scale and 5XSTS were affected by disease severity in the early period. After 12 weeks, the physical parameters improved considerably in most of the mild, moderate, and severe COVID-19 patients. We observed that HGS was normal in almost all patients at the end of 12 weeks. However, 5XSTS tests were still slow in most of the patients. These results suggest that muscle strength improves over time, but rehabilitation programs are needed to improve functional mobility and physical performance in hospitalized patients with COVID-19.

Suppliers
a. Jamar Hydraulic Hand Dynamometer, JA Preston Corporation.
b. IBM SPSS Statistics 20.0 software package, SPSS Inc.

Keywords
COVID-19; Hand strength; Muscle strength; Physical functional performance; Rehabilitation; Sarcopenia

Corresponding author
Ayça Utkan Karasu, MD, Department of Physical Medicine and Rehabilitation, Gazi University Faculty of Medicine, Emniyet Mahallesi, Mevlana Bulvarı, No. 29, 06560 Yenimahalle/?Ankara, Turkey. E-mail address: aycu@tak@gazi.edu.tr.

References
1. Pollard CA, Morran MP, Nestor-Kalinowski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics 2020;52:549–57.
2. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759–65.
3. Bai J, Karakula-Juchnowicz H, Teresinski G, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9.
4. Cipolillo L, Giordano L, Pedulo J, Oliva F, Maffulli N. Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients. J Orthop Surg Res 2020;15:178.
5. Paneroni M, Simonelli C, Saleri M, et al. Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. Am J Phys Med Rehabil 2021;100:105–9.
6. Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci 2020;41:3039–56.
7. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.
8. Soares MN, Eggelbusch M, Naddaf E, et al. Skeletal muscle alterations in patients with acute COVID-19 and post-acute sequelae of COVID-19. J Cachexia Sarcopenia Muscle 2022;13:11–22.
9. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol 2020;11:1708.
10. Piotrowicz K, Gasowski J, Michel JP, Veronese N. Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clin Exp Res 2021;33:2887–98.
11. Tuzun S, Keles A, Okutan D, Yildiran T, Palamar D. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med 2021;57:653–62.
12. WHO. 2020. Clinical management of COVID-19: interim guidance, 27 May 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCov-clinical-2020.5-eng.pdf. Accessed August 12, 2022.
13. Xiao J, Li X, Xie Y, et al. Maximum chest CT score is associated with progression to severe illness in patients with COVID-19: a retrospective study from Wuhan, China. BMC Infect Dis 2020;20:953.
14. Vaishya R, Jain VK, Iyengar KP. Musculoskeletal manifestations of COVID-19. J Clin Orthop Trauma 2021;17:280–1.
15. Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol 2005;62:1113–7.
16. Kara O, Kara M, Akin ME, Ozczakar L. Grip strength as a predictor of disease severity in hospitalized COVID-19 patients. Heart Lung 2021;50:743–7.
17. Landi F, Calvani R, Martone AM, et al. Normative values of muscle strength across ages in a ‘real world’ population: results from the longevity check-up 7+ project. J Cachexia Sarcopenia Muscle 2020;11:1562–9.
18. Medrinal C, Prieur G, Bonnevie T, et al. Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors. BMC Anesthesiol 2021;21:64.
19. Wang W, Xu C, Ma X, Zhang X, Xie P. Intensive care unit-acquired weakness: a review of recent progress with a look toward the future. Front Med (Lausanne) 2020;7:557989.
20. Ekiz T, Kara M, Ozczakar L. Measuring grip strength in COVID-19: a simple way to predict overall frailty/impairment. Heart Lung 2020;49:853–4.
21. Lord SR, Murray SM, Chapman K, Munro B, Tiedemann A. Sit-to-stand performance depends on sensation, speed, balance, and physiological status in addition to strength in older people. J Gerontol A Biol Sci Med Sci 2002;57:M539–43.
22. Ogura A, Iwasa KP, Tawa H, et al. Impact of the COVID-19 pandemic on phase 2 cardiac rehabilitation patients in Japan. Heart Vessels 2021;36:1184–9.
23. Cuerva C, Sanchez Lopez I, Gil Martinez C, et al. Impact of COVID-19 in nutritional and functional status of survivors admitted in intensive care units during the first outbreak. Preliminary results of the NUTRICOID study. Clin Nutr 2021 Nov 23. [E-pub ahead of print].
24. Trevisson-Redondo B, Lopez-Lopez D, Perez-Boal E, et al. Use of the Barthel Index to assess activities of daily living before and after SARS-COV-19 infection of institutionalized nursing home patients. Int J Environ Res Public Health 2021;18:7258.
25. Hosoda T, Hamada S. Functional decline in hospitalized older patients with coronavirus disease 2019: a retrospective cohort study. BMC Geriatr 2021;21:638.

26. Barker-Davies RM, O’Sullivan O, Senaratne KPP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med 2020;54:949–59.

27. Demeco A, Marotta N, Barletta M, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. J Int Med Res 2020;48:300060520948382.

28. Wang TJ, Chau B, Lui M, Lam GT, Lin N, Humbert S. Physical medicine and rehabilitation and pulmonary rehabilitation for COVID-19. Am J Phys Med Rehabil 2020;99:769–74.